Alejandro Rodriguez-Martinez
Overview
Explore the profile of Alejandro Rodriguez-Martinez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
84
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Garcia-Lozano M, Dragoni F, Gallego P, Mazzotta S, Lopez-Gomez A, Boccuto A, et al.
Bioorg Chem
. 2023 Feb;
133:106408.
PMID: 36801791
Since 2011 Direct Acting antivirals (DAAs) drugs targeting different non-structural (NS) viral proteins (NS3, NS5A or NS5B inhibitors) have been approved for clinical use in HCV therapies. However, currently there...
12.
Hydroxybenzoic Acids as Acetylcholinesterase Inhibitors: Calorimetric and Docking Simulation Studies
Budryn G, Majak I, Grzelczyk J, Szwajgier D, Rodriguez-Martinez A, Perez-Sanchez H
Nutrients
. 2022 Jun;
14(12).
PMID: 35745206
One of the symptoms of Alzheimer's disease (AD) is low acetylcholine level due to high acetylcholinesterase (AChE) activity. For this reason, AChE inhibitors are used in the treatment of AD,...
13.
Gyebi G, Ogunyemi O, Adefolalu A, Lopez-Pastor J, Banegas-Luna A, Rodriguez-Martinez A, et al.
J Biomol Struct Dyn
. 2022 May;
41(11):5022-5044.
PMID: 35635123
The inhibition of capping enzymes such as guanine-N7-methyltransferase (GMT) is an attractive target for regulating viral replication, transcription, virulence, and pathogenesis. Thus, compounds that target the Severe Acute Respiratory Syndrome...
14.
Gyebi G, Ogunyemi O, Adefolalu A, Rodriguez-Martinez A, Lopez-Pastor J, Banegas-Luna A, et al.
J Mol Struct
. 2022 Apr;
1262:133019.
PMID: 35431328
Despite the ongoing vaccination against the life-threatening COVID-19, there is need for viable therapeutic interventions. The S-adenosyl-l-Methionine (SAM) dependent 2-O'-ribose methyltransferase (2'-O-MTase) of the severe acute respiratory syndrome coronavirus 2...
15.
Garcia-Romero R, Martinez de Zabarte Fernandez J, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Canton O, Irastorza-Terradillos I, et al.
Eur J Pediatr
. 2021 May;
180(9):3039-3040.
PMID: 34027626
No abstract available.
16.
Garcia-Romero R, Martinez de Zabarte Fernandez J, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Canton O, Irastorza-Terradillos I, et al.
Eur J Pediatr
. 2021 Apr;
180(9):3029-3038.
PMID: 33880650
Vedolizumab is a humanised monoclonal antibody that binds to integrin α4β7 expressed in T-cells, inhibiting its binding to the mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is specifically expressed in...
17.
Salvador-Martin S, Kaczmarczyk B, Alvarez R, Navas-Lopez V, Gallego-Fernandez C, Moreno-Alvarez A, et al.
Pharmaceutics
. 2021 Jan;
13(1).
PMID: 33429950
Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic...
18.
Salvador-Martin S, Bossacoma F, Pujol-Muncunill G, Navas-Lopez V, Gallego-Fernandez C, Viada J, et al.
J Pediatr Gastroenterol Nutr
. 2020 Aug;
71(4):508-515.
PMID: 32773718
Objectives: Inflammatory bowel disease (IBD) is more complex in children and they will have to live with the disease for much longer. For this reason, it is necessary to optimize...
19.
Salvador-Martin S, Pujol-Muncunill G, Bossacoma F, Navas-Lopez V, Gallego-Fernandez C, Segarra O, et al.
Br J Clin Pharmacol
. 2020 Jun;
87(2):447-457.
PMID: 32478906
Aims: Identifying DNA variants associated with trough serum anti-tumour necrosis factor (TNF) levels could predict response to treatment in inflammatory bowel disease (IBD). To date, no specific studies have been...
20.
Salvador-Martin S, Raposo-Gutierrez I, Navas-Lopez V, Gallego-Fernandez C, Moreno-Alvarez A, Solar-Boga A, et al.
Int J Mol Sci
. 2020 May;
21(9).
PMID: 32397546
Around a 20-30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30%...